Trametinib, a MEK inhibitor, in combination with dabrafenib showed durable anti-tumor activity and acceptable safety in patients with BRAFV600E-mutant metastatic NSCLC in phase 2 trials15–17. Here, MAP2K7 is linked to non-small cell lung carcinoma.